Global Gene Therapy Market Outlook 2020
Gene therapy is a therapeutic technique which replaces damaged proteins in the cell by artificially introducing the DNA into a cell. Majority of the metabolic or genetic disorders are a consequence of either a direct genetic aberration or a dysfunctional/non-functional protein. The attempt to use nucleic acids to correct or erase the genes causing a particular disease is the basis of gene therapy. Despite the fact that gene therapy has not contributed fundamentally to the global pharmaceutical market yet, it is expected to grow at a fast pace over the next decade.
As indicated by the new estimation carried out in our most recent study, the global gene therapy industry can possibly turn into a multi-million dollar industry by the end of 2020, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.
According to RNCOS’ new research report “Global Gene Therapy Market Outlook 2020”, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market, such as phases, geographies, vector types, etc.
The gene therapy market has very few marketed products. The market is majorly in the research phase from which most of its revenue is generated. The report also provides the sales of major marketed gene therapy products and the list of the products in clinical/pre-clinical research along with their clinical phases.
The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products. The study highlights the applications for which the investments have been received.
Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and ‘difficult to treat’ cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. The report provides the market analysis of key therapeutic areas along with the forecast till 2020.
North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.
RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry’s growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.
As indicated by the new estimation carried out in our most recent study, the global gene therapy industry can possibly turn into a multi-million dollar industry by the end of 2020, as new products, particularly those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth.
According to RNCOS’ new research report “Global Gene Therapy Market Outlook 2020”, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the study provides a comprehensive overview of various aspects of the clinical trials in the gene therapy market, such as phases, geographies, vector types, etc.
The gene therapy market has very few marketed products. The market is majorly in the research phase from which most of its revenue is generated. The report also provides the sales of major marketed gene therapy products and the list of the products in clinical/pre-clinical research along with their clinical phases.
The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms, which are aiding them to develop new products. The study highlights the applications for which the investments have been received.
Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and ‘difficult to treat’ cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. The report provides the market analysis of key therapeutic areas along with the forecast till 2020.
North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.
RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry’s growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understanding the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GENE THERAPY - AN INTRODUCTION
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-Mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Viral Vectors
3.3.1.1 Adenoviral Vectors
3.3.1.2 Adeno-associated Virus Vectors
3.3.1.3 Retroviral Vectors
3.3.1.4 Lentiviral Vectors
3.3.2 Non Viral Vectors
3.3.2.1 Naked DNA/Plasmid Vectors
3.3.2.2 Oligonucleotides
3.3.2.3 Liposomes, Lipoplexes and Polyplexes
3.3.2.4 Gene-Activated Matrix
4. INDUSTRY OVERVIEW
4.1 Market Drivers
4.1.1 Failure of Conventional Therapies to Treat Cancers
4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
4.1.4 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 Stringent Regulatory Laws & Safety Concerns
4.2.2 Pitfalls in Current Technique
4.2.3 High Cost of the Gene Therapy Drugs
4.3 Market Opportunities
4.3.1 Approval of Gene Therapy Drug in Europe
4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
4.4 Industry Trends
4.4.1 Gene Silencing: Gaining Momentum
4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.4.4 Nanotechnology: Empowering Gene Therapy
4.4.5 Gene Therapy: A New Hope to Treat Blindness
4.4.6 Gene Therapy: Potential Cure for Cancer
4.5 Winning Imperatives
4.5.1 Investment in R&D Activities
5. CLINICAL TRIAL ASSESSMENT & PIPELINE ANALYSIS
5.1 Clinical Trials
5.1.1 By Geography
5.1.2 By Indication
5.1.3 By Gene Type
5.1.4 By Vector
5.1.5 By Clinical Trial Phase
5.2 Pipeline Analysis
6. GENE THERAPY MARKET - REGULATORY LANDSCAPE & REIMBURSEMENT SCENARIO
6.1 Regulatory Landscape
6.1.1 US
6.1.2 Canada
6.1.3 Europe
6.1.4 Japan
6.1.5 China
6.1.6 India
6.1.7 Australia
6.2 Reimbursement Scenario in Global Market
7. MARKETED GENE THERAPIES
7.1 Neovasculgen
7.2 Glybera
7.3 Gendicine, Rexin-G, Oncorine
7.3.1 Gendicine
7.3.2 Rexin G
7.3.3 Oncorine
8. GLOBAL GENE THERAPY MARKET
9. GENE THERAPY MARKET BY APPLICATION
9.1 Oncology
9.2 Cardiovascular Diseases
9.3 Infectious Diseases
9.4 Neurological Diseases
9.5 Genetic Diseases
9.6 Others
10. GLOBAL GENE THERAPY MARKET SIZE BY GEOGRAPHY
10.1 North America
10.2 Europe
10.3 Asia
10.4 Rest of the World (RoW)
11. COMPETITIVE LANDSCAPE
11.1 Strategies Adopted by Various Players
11.1.1 Strategic Collaborations
11.1.2 Acquisitions
11.1.3 Funding & Investments
11.2 Companies Progress in Gene Therapy In 2015
12. KEY PLAYERS ANALYSIS (BUSINESS DESCRIPTION, CLINICAL PIPELINE, RECENT DEVELOPMENTS, STRENGTHS & WEAKNESSES)
12.1 Spark Therapeutics, LLC
12.2 ViroMed Co. Ltd. dba VM BioPharma
12.3 Advantagene Inc.
12.4 Bluebird Bio
12.5 Sanofi
12.6 Vical Inc.
12.7 Oxford BioMedica Plc
12.8 Genethon
12.9 UniQure N.V.
12.10 Human Stem Cells Institute
12.11 Shanghai Sunway Biotech Co. Ltd.
12.12 Sibiono GeneTech Co. Ltd.
2. RESEARCH METHODOLOGY
3. GENE THERAPY - AN INTRODUCTION
3.1 Classification of Gene Therapy Techniques
3.2 Physical Methods of Gene Transfer
3.2.1 Electroporation
3.2.2 Hydrodynamic
3.2.3 Microinjection
3.2.4 Particle Bombardment
3.2.5 Ultrasound-Mediated Transfection
3.3 Vectors for Gene Therapy
3.3.1 Viral Vectors
3.3.1.1 Adenoviral Vectors
3.3.1.2 Adeno-associated Virus Vectors
3.3.1.3 Retroviral Vectors
3.3.1.4 Lentiviral Vectors
3.3.2 Non Viral Vectors
3.3.2.1 Naked DNA/Plasmid Vectors
3.3.2.2 Oligonucleotides
3.3.2.3 Liposomes, Lipoplexes and Polyplexes
3.3.2.4 Gene-Activated Matrix
4. INDUSTRY OVERVIEW
4.1 Market Drivers
4.1.1 Failure of Conventional Therapies to Treat Cancers
4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
4.1.3 Rising Incidence of Chronic and Life Threatening Diseases
4.1.4 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 Stringent Regulatory Laws & Safety Concerns
4.2.2 Pitfalls in Current Technique
4.2.3 High Cost of the Gene Therapy Drugs
4.3 Market Opportunities
4.3.1 Approval of Gene Therapy Drug in Europe
4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity
4.4 Industry Trends
4.4.1 Gene Silencing: Gaining Momentum
4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy
4.4.4 Nanotechnology: Empowering Gene Therapy
4.4.5 Gene Therapy: A New Hope to Treat Blindness
4.4.6 Gene Therapy: Potential Cure for Cancer
4.5 Winning Imperatives
4.5.1 Investment in R&D Activities
5. CLINICAL TRIAL ASSESSMENT & PIPELINE ANALYSIS
5.1 Clinical Trials
5.1.1 By Geography
5.1.2 By Indication
5.1.3 By Gene Type
5.1.4 By Vector
5.1.5 By Clinical Trial Phase
5.2 Pipeline Analysis
6. GENE THERAPY MARKET - REGULATORY LANDSCAPE & REIMBURSEMENT SCENARIO
6.1 Regulatory Landscape
6.1.1 US
6.1.2 Canada
6.1.3 Europe
6.1.4 Japan
6.1.5 China
6.1.6 India
6.1.7 Australia
6.2 Reimbursement Scenario in Global Market
7. MARKETED GENE THERAPIES
7.1 Neovasculgen
7.2 Glybera
7.3 Gendicine, Rexin-G, Oncorine
7.3.1 Gendicine
7.3.2 Rexin G
7.3.3 Oncorine
8. GLOBAL GENE THERAPY MARKET
9. GENE THERAPY MARKET BY APPLICATION
9.1 Oncology
9.2 Cardiovascular Diseases
9.3 Infectious Diseases
9.4 Neurological Diseases
9.5 Genetic Diseases
9.6 Others
10. GLOBAL GENE THERAPY MARKET SIZE BY GEOGRAPHY
10.1 North America
10.2 Europe
10.3 Asia
10.4 Rest of the World (RoW)
11. COMPETITIVE LANDSCAPE
11.1 Strategies Adopted by Various Players
11.1.1 Strategic Collaborations
11.1.2 Acquisitions
11.1.3 Funding & Investments
11.2 Companies Progress in Gene Therapy In 2015
12. KEY PLAYERS ANALYSIS (BUSINESS DESCRIPTION, CLINICAL PIPELINE, RECENT DEVELOPMENTS, STRENGTHS & WEAKNESSES)
12.1 Spark Therapeutics, LLC
12.2 ViroMed Co. Ltd. dba VM BioPharma
12.3 Advantagene Inc.
12.4 Bluebird Bio
12.5 Sanofi
12.6 Vical Inc.
12.7 Oxford BioMedica Plc
12.8 Genethon
12.9 UniQure N.V.
12.10 Human Stem Cells Institute
12.11 Shanghai Sunway Biotech Co. Ltd.
12.12 Sibiono GeneTech Co. Ltd.
LIST OF FIGURES:
Figure 4-1: Global - Venture Capitalist Investments in Gene Threapy Product Development (Billion US$), 1999 to H1 2015
Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents till July, 2015
Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries till July, 2015
Figure 5-4: Global - Gene Therapy Clinical Trials by Indication till July, 2015
Figure 5-5: Global - Gene Therapy Clinical Trials by Types of Gene Transferred till July, 2015
Figure 5-6: Global - Gene Therapy Clinical Trials by Percentage of Vectors Used till July, 2015
Figure 5-7: Global - Gene Therapy Clinical Trials by Phase till July, 2015
Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 & 2014
Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
Figure 9-3: Global - Gene Therapy Oncology Market (Million US$), 2014, 2015 & 2020
Figure 9-4: Global - Gene Therapy Oncology Market by Geography (%), 2015
Figure 9-5: Global - Gene Therapy Cardiovascular Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-6: Global - Gene Therapy Cardiovascular Disease Market by Geography (%), 2015
Figure 9-7: Global - Gene Therapy Infectious Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-8: Global - Gene Therapy Infectious Disease Market by Geography (%), 2015
Figure 9-9: Global - Gene Therapy Neurological Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-10: Global - Gene Therapy Neurological Disease Market by Geography (%), 2015
Figure 9-11: Global - Gene Therapy Genetic Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-12: Global - Gene Therapy Genetic Disease Market, by Geography (%), 2015
Figure 9-13: Global - Gene Therapy Other Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-14: Global - Gene Therapy Other Disease Market by Geography (%), 2015
Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 & 2013)
Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
Figure 11-5: Companies Progress in Gene Therapy till 2015
Figure 4-1: Global - Venture Capitalist Investments in Gene Threapy Product Development (Billion US$), 1999 to H1 2015
Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-July 2015)
Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents till July, 2015
Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries till July, 2015
Figure 5-4: Global - Gene Therapy Clinical Trials by Indication till July, 2015
Figure 5-5: Global - Gene Therapy Clinical Trials by Types of Gene Transferred till July, 2015
Figure 5-6: Global - Gene Therapy Clinical Trials by Percentage of Vectors Used till July, 2015
Figure 5-7: Global - Gene Therapy Clinical Trials by Phase till July, 2015
Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 & 2014
Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
Figure 9-3: Global - Gene Therapy Oncology Market (Million US$), 2014, 2015 & 2020
Figure 9-4: Global - Gene Therapy Oncology Market by Geography (%), 2015
Figure 9-5: Global - Gene Therapy Cardiovascular Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-6: Global - Gene Therapy Cardiovascular Disease Market by Geography (%), 2015
Figure 9-7: Global - Gene Therapy Infectious Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-8: Global - Gene Therapy Infectious Disease Market by Geography (%), 2015
Figure 9-9: Global - Gene Therapy Neurological Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-10: Global - Gene Therapy Neurological Disease Market by Geography (%), 2015
Figure 9-11: Global - Gene Therapy Genetic Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-12: Global - Gene Therapy Genetic Disease Market, by Geography (%), 2015
Figure 9-13: Global - Gene Therapy Other Disease Market (Million US$), 2014, 2015 & 2020
Figure 9-14: Global - Gene Therapy Other Disease Market by Geography (%), 2015
Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 & 2013)
Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 & 2020
Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
Figure 11-5: Companies Progress in Gene Therapy till 2015
LIST OF TABLES:
Table 4-1: US - Gene Therapies under Development
Table 4-2: Europe - Gene Therapies under Development
Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
Table 4-4: Current Status of Clinical Trials for Hemophilia
Table 5-1: Human Gene Transfer Trials Approved by Condition till 2012
Table 5-2: Key Ongoing Gene Therapy Clinical Trials
Table 6-1: China - Key Players and their Products in Gene Therapy
Table 9-1: Vectors Used for Cardiovascular Gene Transfer
Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 4-1: US - Gene Therapies under Development
Table 4-2: Europe - Gene Therapies under Development
Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
Table 4-4: Current Status of Clinical Trials for Hemophilia
Table 5-1: Human Gene Transfer Trials Approved by Condition till 2012
Table 5-2: Key Ongoing Gene Therapy Clinical Trials
Table 6-1: China - Key Players and their Products in Gene Therapy
Table 9-1: Vectors Used for Cardiovascular Gene Transfer
Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy
